Sevelamer and CKD-associated cardiovascular disease: going further, but far from there
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2013
Editora
NATURE PUBLISHING GROUP
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
CANZIANI, Maria E. F.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
KIDNEY INTERNATIONAL, v.84, n.3, p.429-431, 2013
Resumo
Cardiovascular disease is a major complication of chronic kidney disease (CKD), and current data support its link to mineral metabolism disturbances. However, there is an intense debate over whether CKD-mineral and bone disorder therapy could change the cardiovascular burden in CKD. The study by Maizel and colleagues shows the benefits of a phosphate binder, sevelamer, for the progression of aortic stiffness and endothelial dysfunction as well as left ventricular dysfunction and hypertrophy in mice with CKD.
Palavras-chave
Referências
- Chue CD, 2013, J AM SOC NEPHROL, V24, P842, DOI 10.1681/ASN.2012070719
- Custodio MR, 2012, NEPHROL DIAL TRANSPL, V27, P1437, DOI 10.1093/ndt/gfr447
- Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
- Graciolli FG, 2009, NEPHROL DIAL TRANSPL, V24, P1416, DOI 10.1093/ndt/gfn686
- Maizel J, 2013, KIDNEY INT, V84, P491, DOI 10.1038/ki.2013.110
- Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
- Neves KR, 2004, KIDNEY INT, V66, P2237, DOI 10.1111/j.1523-1755.2004.66013.x
- Yilmaz MI, 2012, AM J KIDNEY DIS, V59, P177, DOI 10.1053/j.ajkd.2011.11.007